Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Published on by Global Academic Awards

Dr. Jesus Alonso Gandara Mireles | Pharmacology, Toxicology and Pharmaceutical Science | Young Scientist Award

Researcher,  National Polytechnic Institute,  Mexico.

Jesús Alonso Gándara Mireles is an exemplary candidate for the Research for Young Scientist Award, with extensive qualifications in biotechnology. He holds a Bachelor’s degree and multiple master’s degrees, culminating in a PhD focused on pharmacokinetics and pharmacogenetics in oncology. Currently completing a Postdoctoral Fellowship at the National Polytechnic Institute, Jesús conducts research aimed at optimizing chemotherapy for pediatric cancer patients. His experience includes prestigious internships at the University at Buffalo and the University of San Diego, enhancing his expertise. As a member of key professional organizations, he demonstrates a strong commitment to advancing personalized medicine and improving patient outcomes.

Publication Profile :

Scopus

Educational Background :

Jesús’s educational achievements are impressive and relevant to his research interests. He holds a Bachelor’s degree in Biotechnology with a biomedical focus, followed by a Master’s in Molecular and Cellular Biology, a Master’s in Human Genetics, and a Master’s in Clinical Pharmacokinetics. His PhD, centered on pharmacokinetics and pharmacogenetics in oncology, underscores his specialized knowledge in this vital area of research. This rigorous academic training has equipped him with the necessary skills to tackle complex scientific problems in the field of cancer treatment.

Professional Experiences :

Jesús Alonso Gándara Mireles has accumulated extensive professional experience in biotechnology and clinical research, particularly in the fields of pharmacogenetics and pharmacokinetics. Currently, he is completing a Postdoctoral Fellowship at the National Polytechnic Institute (IPN), focusing on the pharmacokinetics of oncology agents in pediatric patients. His previous internships include significant roles in Clinical Pharmacokinetics at the National Institute of Pediatrics and Pediatric Cancer Pharmacology at the University at Buffalo. He also engaged in research on Pediatric Cancer Genetics at the University of San Diego. His work aims to optimize treatment strategies and reduce chemotherapy-induced adverse effects in childhood cancer.

Research Contribution  :

Throughout his career, Jesús has gained valuable research experience through multiple internships. His exposure to pharmacokinetics and pharmacogenetics at prestigious institutions, including the University at Buffalo and the University of San Diego, highlights his capability to engage with leading experts and contribute to groundbreaking research. His current work focuses on optimizing chemotherapy for children by reducing adverse effects through personalized medicine, emphasizing his innovative approach to healthcare challenges.

Awards And Achievements :

Jesús Alonso Gándara Mireles has earned notable recogn ition throughout his academic and research career. As a member of the National System of Researchers (CONACYT) at Level 1, he has demonstrated his commitment to advancing scientific knowledge. His research contributions have been acknowledged through prestigious internships, including those at the National Institute of Pediatrics and the University at Buffalo. Additionally, Jesús is an active member of the International Society of Pediatric Oncology (SIOP) and the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM). These affiliations reflect his dedication to pediatric oncology and personalized medicine, underscoring his impactful contributions to the field.

Conclusion : 

Jesús Alonso Gándara Mireles is an outstanding candidate for the Research for Young Scientist Award. His impressive educational background, significant research experience, and active participation in professional networks make him a valuable contributor to the field of biotechnology and pediatric oncology. His work has the potential to greatly improve treatment outcomes for children with cancer, demonstrating his commitment to advancing scientific knowledge and enhancing patient care. Therefore, I strongly endorse his nomination for this esteemed award.

Publication Top Notes :

  • “Influence of Age, Gender and Body Mass Index on Intravenous Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery” (2024) – 🏥
  • “Population pharmacokinetics and pharmacodynamics of L-asparaginase and its impact on the development of pancreatitis and hypersensitivity reactions in children with leukemia under treatment” (2024) – 🧬
  • “Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with Acute Lymphoblastic Leukemia” (2024) – 🍽️
  • “Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia” (2023) – ⚗️ Cited by: 3
  • “Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia” (2021) – 🧬 Cited by: 8
  • “Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population” (2021) – 🔬 Cited by: 3

Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Published on by Global Academic Awards

Maryam Tabarzad | Pharmaceutical Science | Best Researcher Award

Assist Prof Dr Maryam Tabarzad, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Iran

Based on Dr. Maryam Tabarzad’s profile, she appears to be a strong candidate for the Best Researcher Award due to several key factors:

Publication profile

google scholar

Educational Background

  • MSc in E-learning in Medical Education (2023): Focused on enhancing lab skills through augmented reality in pharmacy students.
  • PhD in Pharmaceutical Biotechnology (2014): Specialized in DNA aptamers against Coagulation Factor VIII.
  • Pharm.D. (2007): Conducted research on bis(4-nitroaryl-1,4-Dihydropyridine) with pharmacological evaluations.

Professional Experience

  • Assistant Professor: Protein Technology Research Center, Shahid Beheshti University of Medical Science (2014-present).
  • Vice-Chancellor of Research Affairs: Protein Technology Research Center (2018-present).
  • Editorial Roles: Managing Editor for Trends in Peptide and Protein Sciences, Associate Editor for Iranian Journal of Pharmaceutical Research, and Editorial member for Future Natural Products.

Notable Publications

  1. Fathi et al. (2024): Investigated antimicrobial peptides for wound healing, published in Burns (Q2, IF: 3.2).
  2. Fathi et al. (2024): Explored structural features of antimicrobial peptides in Bioorganic Chemistry (Q1, IF: 5.1).
  3. Yazdanicherati et al. (2024): Studied the effect of antimicrobial peptides on gold nanoparticles, published in Modares Journal of Biotechnology.

Teaching Experience

  • Extensive teaching roles in pharmaceutical and medical biotechnology across various institutions, including University of Science and Culture, Gilan University of Medical Sciences, and Shahid Beheshti University of Medical Sciences.

Thesis Supervision

  • Supervised multiple Ph.D. and MSc theses in areas such as biosensors, peptide-nanomolecule interactions, and cancer research.

Conclusion

Dr. Maryam Tabarzad’s impressive academic credentials, significant contributions to pharmaceutical biotechnology, influential editorial roles, and robust teaching and supervisory experience make her a highly suitable candidate for the Best Researcher Award. Her research, particularly in the design and development of antimicrobial peptides and aptamers, along with her leadership in research and education, underscores her excellence in the field.

Publication top notes

Therapeutic applications of nucleic acid aptamers in microbial infections

Aptamers as smart ligands for nano-carriers targeting

Anti-inflammatory activity of bioactive compounds from microalgae and cyanobacteria by focusing on the mechanisms of action

Simultaneous detection of bovine and porcine DNA in pharmaceutical gelatin capsules by duplex PCR assay for Halal authentication

Silymarin antiproliferative and apoptotic effects: insights into its clinical impact in various types of cancer

Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers

Anti-cancer drug delivery using carbohydrate-based polymers

Trends in the design and development of specific aptamers against peptides and proteins

Peptide dendrimers as valuable biomaterials in medical sciences

Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Published on by Global Academic Awards

Assoc Prof Dr. Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Assoc Prof Dr, Patricia Rijo, Universidade Lusófona, Portugal

Assoc Prof Dr. Patricia Rijo is a distinguished academic at Universidade Lusófona in Portugal. With expertise in [mention her field or area of specialization], Dr. Rijo has contributed significantly to [mention any notable contributions or achievements, such as research, publications, or projects]. Her dedication to [mention any relevant causes or academic interests] underscores her commitment to advancing knowledge in her field. Dr. Rijo’s academic leadership and mentorship inspire both colleagues and students alike at Universidade Lusófona.

Publication profile

Scopus

Education

PhD in Pharmacy (specialty in Medicinal Chemistry and Therapeutics) with Distinction, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Master’s Degree (MSc) in Medicinal Chemistry, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Bachelor’s Degree in Chemistry, Faculdade de Ciências da Universidade de Lisboa, 1999.

Professional Experience

Dr. Hyunsook Lee has had a distinguished professional career in academia and research 👩‍🔬. She began as a Research Scientist at Mogam Biotech Research Institute in Korea (1992. Mar – 1994. May) 🔬 and was promoted to Senior Research Scientist (1994. May – 1996. Aug) 🧬. She then transitioned to academia as a Research Assistant Professor at Ewha Womans University (2002. Sept – 2003) 🧪. In 2004, she joined the Dept. of Biological Sciences at Seoul National University (SNU) as an Assistant Professor 📚, advancing to Associate Professor in 2008 and earning early tenure in 2010 🌟. By 2012, she became a full Professor at SNU 🌍. Dr. Lee has also served in several key administrative roles, including Vice Dean of Planning for the College of Natural Sciences (2015 July – 2017 June) 📅, and Dean for Research Affairs at SNU (2021. Feb – 2023. Feb) 🎓. She has been the Head of the AI-Bio Research Center since 2023 🧠🔬 and co-founded Next & Bio in 2019, which later merged with Kolmar Holdings in 2022 💼. Her visiting scientist positions include stints at the Dana Farber Cancer Institute (2010. Aug – 2011. July) 🧬 and Samsung Advanced Institute of Technology (2020. Aug – 2021. Feb) 🏥.

Academic Positions:

Associate Professor at Universidade Lusófona de Humanidades e Tecnologias (ULHT), since June 2020.,Assistant Professor at ULHT (2011-2020).,Coordinator Professor at Escola Superior de Ciências da Saúde (2011-2016).,Assistant at ULHT (2005-2010).,Invited Assistant Professor at Escola Superior de Saúde Ribeiro Sanches (2002-2011).,Monitor at Faculdade de Farmácia da Universidade de Lisboa (2001-2005).

Awards and Honors:

Egon Stahl-Award in Bronze from Society for Medicinal Plant and Natural Product Research (2022).,Various awards for scientific presentations and research contributions.

Additional Skills and Activities:

  • Languages: Proficiency in Portuguese (C2), English (B2), Spanish (B1), French (A2).
  • Supervision: Supervised numerous PhD and Master’s students.
  • Project Leadership: Participation and leadership in multiple research projects.

Publications:

  • Anticancer diterpenes of African natural products: Mechanistic pathways and preclinical developments
    • Authors: Bangay, G., Brauning, F.Z., Rosatella, A., Efferth, T., Rijo, P.
    • Journal: Phytomedicine, 2024, 129, 155634
    • Abstract: This article likely discusses the mechanistic pathways through which diterpenes from African natural products exhibit anticancer properties, as well as their development in preclinical studies.
  • Glycyrrhizic Acid Nanoparticles Subside the Activity of Methicillin-Resistant Staphylococcus aureus by Suppressing PBP2a
    • Authors: Rijo, P., Abuamara, T.M.M., Ali Lashin, L.S., Abd El Maksoud, A.I., Hassan, A.
    • Journal: Pharmaceuticals, 2024, 17(5), 589
    • Abstract: This article likely explores the use of glycyrrhizic acid nanoparticles to combat methicillin-resistant Staphylococcus aureus (MRSA) by targeting the penicillin-binding protein PBP2a.
  • Halimane Derivatives from Plectranthus ornatus Codd. as Novel Anti-cancer Agents
    • Authors: Bangay, G., Brauning, F.Z., Kowalczyk, T., Sitarek, P., Rijo, P.
    • Journal: Biomedicine and Pharmacotherapy, 2024, 174, 116516
    • Abstract: This article likely investigates the anticancer potential of halimane derivatives from Plectranthus ornatus.
  • Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP
    • Authors: Seguin-Devaux, C., Mestrovic, T., Arts, J.J., Rijo, P., Mori, M.
    • Journal: Drug Resistance Updates, 2024, 74, 101069
    • Abstract: This editorial likely outlines the efforts and strategies of the COST Action CA21145 EURESTOP in addressing antibacterial resistance in Europe.
  • Biological Activity of 6,7-Dehydroxyroyleanone and Derivatives Obtained from Plectranthus aliciae (Codd) A.J.Paton
    • Authors: Filipe, M.S., Domínguez-Martín, E.M., Pires, T.C.S.P., Barros, L., Rijo, P.
    • Journal: ACS Omega, 2024, 9(16), pp. 18113–18118
    • Abstract: This article likely details the biological activities of 6,7-dehydroxyroyleanone and its derivatives sourced from Plectranthus aliciae.
  • Exploring the Anticancer Potential of Semisynthetic Derivatives of 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus sp.: An In Silico Approach
    • Authors: Merecz-Sadowska, A., Isca, V.M.S., Sitarek, P., Rijo, P., Zajdel, R.
    • Journal: International Journal of Molecular Sciences, 2024, 25(8)
    • Abstract: This article likely explores the anticancer potential of semisynthetic derivatives of a specific compound from Plectranthus species using computational methods.
  • Anticancer Effects of Abietane Diterpene 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus grandidentatus and Its Semi-Synthetic Analogs: An In Silico Computational Approach
    • Authors: Isca, V.M.S., Sitarek, P., Merecz-Sadowska, A., Rijo, P., Kowalczyk, T.
    • Journal: Molecules, 2024, 29(8), 1807
    • Abstract: This article likely investigates the anticancer effects of abietane diterpene and its analogs from Plectranthus grandidentatus using computational techniques.
  • Antibiotic Coordination Frameworks against Antibiotic Resistance: How to Involve Students through Experimental Practices in the Search for Solutions to Public Health Problems
    • Authors: Domínguez-Martín, E.M., Ntungwe, E., Isca, V.M.S., André, V., Rijo, P.
    • Journal: Journal of Chemical Education, 2024, 101(5), pp. 2045–2051
    • Abstract: This article likely discusses educational strategies to involve students in experimental practices to address antibiotic resistance.
  • The Precious Potential of the Sacred Tree Chamaecyparis obtusa (Siebold & Zucc.) Endl. as a Source of Secondary Metabolites with Broad Biological Applications
    • Authors: Górski, K.M., Kowalczyk, T., Picot, L., Ghorbanpour, M., Sitarek, P.
    • Journal: International Journal of Molecular Sciences, 2024, 25(5), 2723
    • Abstract: This review likely highlights the various biological applications of secondary metabolites derived from Chamaecyparis obtusa.
  • Enhancement of Vitamin C’s Protective Effect against Thimerosal-Induced Neurotoxicity in the Cerebral Cortex of Wistar Albino Rats: An In Vivo and Computational Study
    • Authors: Hassan, A., Mohsen, R., Rezk, A., Abd El Maksoud, A.I., Mohamed, A.F.
    • Journal: ACS Omega, 2024, 9(8), pp. 8973–8984
    • Abstract: This article likely explores the neuroprotective effects of vitamin C against thimerosal-induced toxicity using both in vivo and computational methods.